Detection of platelet-associated immunoglobulins and complement system components in patients with aplastic anemia and hemoblastosis

Background. In addition to anti-HLA-I and anti-HPA-antibodies and specific cytotoxic T-lymphocytes, another cause of immune refractoriness to donor's platelet transfusions could be a platelet-associated different classes immunoglobulins PAIg (G, M, A) and C3 / C4‑components of complement system (PAC3, PAC4). These markers can be detected by flow cytofluorometry of double-stained platelets. The fixation density of immunoglobulins and components of complement systems were measured by the mean fluorescence intensity (MFI).

Objective: to study additional factors that aggravate the course of refractoriness to donor's platelet transfusions in patients with aplastic anemia (AA) and hemoblastosis.

Materials and methods. 77 patients (AA – 47, myelodysplastic syndrome (MDS) – 10, acute myeloid leukemia (AML) – 20) admitted to National Research Centre for Hematology during 11.09.2016–04.28.2018 were enrolled in the study. M / f ratio was 33 / 44, median age was 36 yrs. (19–71 yrs.). Plasmapheresis and cross-matching for PRP selection were used for patients with refractoriness to donor's platelet transfusion. PAIg (G, M, A) and PAC3 / C4 detection and density (MFI) were evaluated in all patients by flow cytofluorometry of doublestained platelets (CD41a-PE; IgA, M, G-FITC; C3 / C4‑FITC) and MFI measurement. Patients with AA were investigated on different stages of therapy and if refractoriness to donor's platelet transfusion is developed. Blood donors (n = 28) MFI measurement results were established as negative control.

Results. It was found that MFI PAIgG/M/А and PAC3/С4 was higher in all groups of the patients (АА, MDS, AML), as compared with donors. MFI of PAIgM and PAIgA in patients were significant higher than MFI of PAIgG and PAC3 / C4. Combination of PAIgM / A, PAIgM / C3 / C4 and PAIgA / C3 / C4 were more frequent. Multiple transfusions of PRP were associated with PAIgA and PAC3 detection. Development of refractoriness to donor's platelet transfusions was accompanied by alloantibodies (HLA-I, HPA) and PAIgM, PAC4 detection. In patients of AA group during development of refractoriness to donor's platelet transfusions and multiple infection complications the high density of PAIgM and PAIgA were identified. Relapse of AA was accompanied MFI of PAC3 density increment.

Conclusion. In addition to application of a certain transfusion therapy algorithm it is also necessary to detect PAIg (G, M, A) and PAC3 / C4 for prediction of severe refractoriness to donor's platelet transfusions.

1. Savchenko V.G. Diagnostic algorithms and treatment protocols for blood diseases. Moscow: Praktika, 2018. Рр. 1006‒1255. (In Russ.).

2. Corazza M. Hranchook M. Massive blood transfusion therapy. AANA J 2000;68(4):311–4.

3. Fletcher C.H., DomBourian M.G., Millward P.A. Platelet transfusion for patients with cancer. Cancer Control 2015;22(1):47–51. DOI: 10.1177/107327481502200107.

4. Zotikov E.A., Babaeva A.G., Golovkina L.L. Platelets and antiplatelet antibodies. Moscow: Monolit, 2003. 125 p. (In Russ.).

5. Rakhmani A.F., Mikhailova E.A., Dubinkin I.V. et al. Refractoriness to donor platelets transfusion in patients with aplastic anemia and hemoblastosis. Onkogematologiya = Oncohematology 2018;13(2):62‒72. (In Russ). DOI: 10.17650/18188346-2018-13-2-62-72.

6. Hod E., Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142(3):348–60. DOI: 10.1111/j.1365-2141.2008.07189.x.

7. Forest S.K., Hod E.A. Management of the platelet refractory patient. Hematol Oncol Clin North Am 2016;30(3):665–77. DOI: 10.1016/j.hoc.2016.01.008.

8. Kiefel V., Konig C., Kroll H., Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41(6):766–70. DOI:10.1046/j.15372995.2001.41060766.x.

9. Mazurov A.V. Platelet physiology and pathology. Moscow: Litterra, 2011. 456 p. (In Russ.).

10. Wallington T. Essential immunology for transfusion medicine. In: Practical Transfusion Medicine, 3rd edn. Eds.: M.F. Murphy, D.H. Pamphilon. Blackwell Publishing Ltd, 2009. DOI: 10.1002/9781444311761.ch2.

11. Sayyadi M., Shaiega M., Zarif M. et al. Platelet transfusion outcome and flow cytometric monocyte phagocytic assay (FMPA). Arch Iran Med 2016;19(6):426– 9. DOI: 0161906/AIM.0010.

12. He Y., Zhao Y.X., Zhu M.Q. et al. Detection of autoantibodies against platelet glycoproteins in patients with immune thrombocytopenic purpura by flow cytometric immunobead array. Clin Chim Acta 2013;415:176–80. DOI: 10.1016/j.cca.2012.10.035.

13. Huh H.J., Park C.J., Kim S.W. et al. Flow cytometric detection of platelet-associated immunoglobulin in patients with immune thrombocytopenic purpura and nonimmune thrombocytopenia. Ann Clin Lab Sci 2009;39(3):283–8.

14. Romero-Guzmán L.T., López-Karpovitch X., Paredes R. et al. Detection of plateletassociated immunoglobulins by flow cytometry for the diagnosis of immune thrombocytopenia: a prospective study and critical review. Haematologica 2000;85(6):627–31.

15. Peerschke E.I., Yin W., Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol 2008;632:81–91. DOI: 10.1007/978-0-387-78952-1_7.

16. Kiefel V., Freitag E., Kroll H., Santoso S. et al. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/ IX in patients with thrombocytopenia. Ann Hematol 1996;72(4):280–5.

17. Myers T., Kim B., Steiner M., Baldini M. Platelet-associated complement C3 in immune thrombocytopenic purpura. Blood 1982;59(5):1023–8.

18. Panzer S., Szamait S., Bödeker R.H. et al. Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders. Am J Hematol 1986;23(2):89– 99. DOI: 10.1002/ajh.2830230203.

19. Andrews R.K., Gardiner E.E. Basic mechanisms of platelet receptor shedding. Platelets 2017;28(4):319–24. DOI: 10.1080/09537104.2016.1235690.

20. Bender M., Stegner D., Nieswandt B. Model systems for platelet receptor shedding. Platelets 2017;28(4):325–32. DOI: 10.1080/09537104.2016.1195491.

21. Gardiner E.E., Al-Tamimi M., Andrews R.K., Berndt M.C. Platelet receptor shedding. Methods Mol Biol 2012;788:321–39. DOI: 10.1007/978-161779-307-3_22.

22. Manis J.P., Silberstein L.E. Platelet refractoriness: It’s not the B-all and endall. Blood 2016;127(14):1740–1. DOI: 10.1182/blood-2016-02-695437.

23. Mikhailova E.A. Program treatment of aplastic anemia patients. In: V.G. Savchenko, E.A. Mikhailova, E.N. Ustinova, G.A. Klyasova. Program treatment of leukemia. Moscow: Praktika, 2018. Рр. 328-342. (In Russ.).

24. Killick S., Bown N., Cavenagh J. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016;172(2):187–207. DOI: 10.1111/bjh.13853.

25. Bevans M.F., Shalabi R.A. Management of patients receiving antithymocyte globulin for aplastic anemia and myelodysplastic syndrome. Clin J Oncol Nurs 2004;8(4):377–82. DOI: 10.1188/04.CJON.377-382.

26. Cheson B.D., Bennett J.M., Kopecky K.J. et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21(24):4642–9. DOI: 10.1200/JCO.2004.99.116.

27. Carubbi C., Masselli E., Gesi M. et al. Cytofluorimetric platelet analysis. Semin Thromb Hemost 2014;40(1):88–98. DOI: 10.1055/s-0033-1363472.

28. Sarkar R.S., Philip J., Jain N. Detection and identification of platelet-associated alloantibodies by a solid-phase modified antigen capture elisa (MACE) technique and its correlation to platelet refractoriness in multi platelet concentrate transfused patients. Indian J Hematol Blood Transfus 2015;31(1):77–84. DOI: 10.1007/s12288014-0374-4.